These include immunohistochemical analysis of CDX2 expression for prognostic stratification, tumor stroma examination for prognostic assessment, and TILs’ evaluation for both prognostic and predictive purposes, alongside ongoing research exploring genetic profiling with prognostic implications in advanced CRC, and genotyping through liquid biopsy-derived circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs) [11,23,25,26,27,28]. The gene discussed is CDX2; the disease is neoplasm.